SANTA CLARA, CA – Rebus Biosystems Inc, (“Rebus Bio”, “Rebus”), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, today announced Danilo Tait as the newest member of its leadership team. Tait, who holds a PhD in molecular biology from the Max-Planck Institute for Molecular Genetics and an MBA from SMC University in Switzerland, will lead the innovative spatial omics company’s commercialization drive across Europe, the Middle East and Africa (EMEA).

San Francisco – Sept. 20, 2021 – Illumina Ventures, an independently-managed, healthcare-focused venture firm, announced today the closing of its second investment fund with total commitments of $325 million, bringing its total capital under management to $560 million. The latest fund is anchored by Illumina, Inc. (Nasdaq: ILMN), with the majority of the total committed capital from other strategic and financial investors, including the Ireland Strategic Investment Fund (ISIF). The fund will support early-stage companies that are pioneering breakthroughs in life science tools, clinical diagnostics, therapeutics platforms, digital health, and other applications of genomics…

SANTA CLARA, CA – Rebus Biosystems, Inc., (“Rebus Bio”), an Illumina Ventures-backed life science technology company creating revolutionary tools to advance spatial omics research, today announced Tarif Awad, a highly experienced technical and commercial leader within the world of life sciences, has joined Rebus Bio as VP Scientific Affairs.

SANTA CLARA, Calif. – Rebus Biosystems, Inc., a venture-backed Silicon Valley-based life science technology company creating revolutionary tools to enable spatial omics research without compromise, today announced the appointment of Neil Kennedy as Chief Commercial Officer (CCO) and Scott Kothlow as Chief Financial Officer (CFO).

SANTA CLARA, Calif. – Rebus Biosystems, Inc., a life science technology company creating revolutionary tools to enable spatial omics research without compromise, today announced the launch of the Rebus Esper^TM spatial omics platform. The new spatial omics platform will allow researchers to better understand the biology of tissues and lead to advancements in neuroscience, cancer, infectious disease and immunology.

SANTA CLARA, Calif. — Rebus Biosystems, Inc., a life science technology company building innovative tools to enable spatial omics without compromise, today announced the closing of a $20 million Series B financing round, led by Illumina Ventures and joined by Lifecore Partners, Ncore Ventures, Xolon Invest, CTK Investments, Ray Co., Ltd., Seegene Medical Foundation, LabGenomics Co., Ltd., and Timefolio Asset Management.